Developments in Cellular Therapy

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts trends across cellular therapies. CAR-T Cell clinical trials and industry interactions are depicted. In particular, a clinical trial overview involving CAR T cells worldwide solid tumors is illustrated.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetical

Table of Contents

Developments in Cellular TherapyInnovations across Cellular Therapy and Skin Testing CAR-T Therapies’ Progress across Inflammatory DiseasesTest Kits Developed as Alternative Methods for Animal Testing Novel Approach for Treating Cancer Using Natural Killer Receptor T CellsAllogeneic Therapies for Oncological Conditions CAR T-Cell Solid Tumor Clinical Trials and Industry InteractionsClinical Trial Overview Involving CAR-T Cells in Solid Tumors Industry Interactions

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.